Tagged with GE

Stallergenes Can you highlight some of the more recent milestones for Stallergenes? Stallergenes has been successful over recent years for several reasons, the first of which is the growth of the group. On average we have grown 15% meaning in the past decade our sales have quadrupled our turnover. These results…

Cegedim Deutschland GmbH You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process of both companies and what were the main synergies between Cegedim and Dendrite in the German context? Germany offered a…

Boehringer Ingelheim France There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these new facilities here at Paris Biopark. What does this express about the moves Boehringer Ingelheim is taking in France and…

Biogen Idec Germany Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The growth potential of the biotech industry is incomparable to any other sector in the pharmaceutical industry, and the entire industry…

GEMME Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap has been narrowed very quickly as highlighted by public opinion and the fact everyone knows about generic drugs, but how…

IMS Health Germany Could you give us a brief introduction to IMS’ business model? What would you say are the main challenges encountered today in the German market for IMS? IMS has been the partner of the pharmaceutical industry for over fifty years and has evolved alongside it. IMS today is the partner…

Pfizer Argentina You were General Manager of Pfizer Peru and Pfizer Venezuela before taking on the challenge of the Argentinean market. How difficult was the experience of adjusting to this unique environment? One of the things that a manager learns quickly in Latin America is how to deal with the volatility and…

Argentine Ministry of Science ¿Porque fue creado en Ministerio de Ciencia y Tecnología, con que visión? Muchos países están aportando importancia a la ciencia y tecnología y representa la razón del desarrollo económico y social de esos mismos países. El ministerio en Argentina se creó en ese sentido, para ayudar a transformar el conocimiento…

Baxter Germany Next year Baxter will accomplish its 50th anniversary in Germany. In the context of its celebration, what would you highlight as the main achievements of the company especially since you took the reigns of the German operations? Baxter Germany has grown steadily in the German market primarily thanks to its…

DKFZ - German Cancer Research Center The DKFZ – German Cancer Research Center – is Germany’s largest cancer research institute with an international recognition recently coroneted with the Nobel Prize to Mr Harald zur Hausen for the HPV vaccine. What were the set of values and visions that allowed the DKEZ to have such a prominent…

Janssen-Cilag Argentina When we spoke to Javier Lombar of IMS Argentina, he explained that a lot of multinational companies use Argentina as a base for regional operations. How does Janssen-Cilag operate in this Latin American context, and what role does the Argentinean operation play in Janssen-Cilag’s plans? Janssen-Cilag sees the pharmaceutical business…

TEVA Germany The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process continued with the recent acquisition of AWD Pharma in 2008. What as the impact of such acquisitions in your German…